New study from Taiwan.
"This population-based cohort study demonstrated that statin use significantly decreased the mortality of PCa patients, and that this risk was inversely associated with the cumulative DDD of simvastatin therapy."
"Analysis of the cumulative defined daily dose (DDD) indicated that patients who were prescribed simvastatin ≥ 180 DDD had a dramatically decreased risk of death from PCa" - 37% less risk.
Authors start by saying that "we investigated the effect of two types of statins (simvastatin and lovastatin)", but there is no other reference to lovastatin in the Abstract.
-Patrick
ncbi.nlm.nih.gov/pubmed/296...
Front Pharmacol. 2018 Mar 22;9:225. doi: 10.3389/fphar.2018.00225. eCollection 2018.
Simvastatin Therapy for Drug Repositioning to Reduce the Risk of Prostate Cancer Mortality in Patients With Hyperlipidemia.
Chen YA1, Lin YJ2, Lin CL1,3, Lin HJ4,5, Wu HS2,6, Hsu HY1, Sun YC7, Wu HY8, Lai CH1,6,8,9, Kao CH1,10,11.
Author information
1
Graduate Institute of Basic Medical Science, School of Medicine, College of Medicine, China Medical University, Taichung, Taiwan.
2
Department of Medical Research, School of Chinese Medicine, China Medical University and Hospital, Taichung, Taiwan.
3
Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan.
4
Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan.
5
Division of Gastroenterology and Hepatology, Department of Internal Medicine, Shuang-Ho Hospital, New Taipei City, Taiwan.
6
Department of Nursing, Asia University, Taichung, Taiwan.
7
Department of Laboratory Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan.
8
Department of Microbiology and Immunology, Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
9
Molecular Infectious Disease Research Center, Chang Gung Memorial Hospital, Linkou, Taiwan.
10
Department of Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan.
11
Department of Nuclear Medicine, PET Center, China Medical University Hospital, Taichung, Taiwan.
Abstract
Prostate cancer (PCa) is one of the most commonly diagnosed cancers in the western world, and the mortality rate from PCa in Asia has been increasing recently. Statins are potent inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase and are commonly used for treating hyperlipidemia, with beneficial effects for cardiovascular disease and they also exhibit anti-cancer activity. However, the protective effects of statins against PCa are controversial. In this study, we investigated the effect of two types of statins (simvastatin and lovastatin) and the mortality rate of PCa patients by using the Taiwan National Health Insurance Research Database (NHIRD). A total of 15,264 PCa patients with hyperlipidemia records and medical claims from the Registry of Catastrophic Illness were enrolled. The patients were divided into two cohorts based on their statin use before the diagnosis of PCa: statin users (n = 1,827) and non-statin users (n = 1,826). The results showed that patients who used statins exhibited a significantly reduced risk of mortality from PCa [adjusted hazard ratio (HR) = 0.84, 95% CI = 0.73-0.97]. Analysis of the cumulative defined daily dose (DDD) indicated that patients who were prescribed simvastatin ≥ 180 DDD had a dramatically decreased risk of death from PCa (adjusted HR = 0.63; 95% CI = 0.51-0.77). This population-based cohort study demonstrated that statin use significantly decreased the mortality of PCa patients, and that this risk was inversely associated with the cumulative DDD of simvastatin therapy. The results of this study revealed that statins may be used for drug repositioning and in the development of a feasible approach to prevent death from PCa.
KEYWORDS:
HMG-CoA reductase; cohort study; hyperlipidemia; prostate cancer; statin
PMID: 29623039 PMCID: PMC5874326 DOI: 10.3389/fphar.2018.00225